Navigation Links
Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Date:10/21/2008

TOKYO, October 22 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, has entered into a binding letter of agreement with ASKA Pharmaceuticals Co., Ltd. ("ASKA", TSE First Section Index: 4514) for the commercialization of the emergency contraceptive pill SOH-075 (NorLevo(R)).

NorLevo(R) is an oral emergency contraceptive "morning after pill" which is used to prevent unwanted pregnancy after unprotected intercourse. NorLevo(R) contains only levonorgestrel as an active ingredient. The dosing is started within 72 hours after unprotected sexual intercourse. NorLevo(R) was first launched in Europe in 1999 and is currently approved in some 60 countries; the product being both safe and effective as an oral emergency contraceptive for post-coital use. Sosei acquired the exclusive distribution rights to the product in Japan from HRA Pharma. The Phase III study was completed in October 2008, and filing of the NDA in Japan is planned for the first half of 2009.

Under the terms of the agreement Sosei will be responsible for Development and registration and ASKA for sales and marketing. A joint committee will be established to oversee all the commercialisation activities. As part of the deal structure, Sosei will receive upfront and milestone payments as well as a significant portion of net sales. ASKA will also acquire shares of Sosei.

With its current product line-up, which includes oral contraceptive pills and infertility drugs, ASKA has taken a significant share of the Japanese obstetric and gynaecologic market. Now, as the anticipated marketing of a menopause disorder patch at the beginning of 2009 approaches, ASKA is focusing on further enhancement of its position in these therapeutic areas.

The agreement underscores Sosei's wish to make a contribution to women's health in Japan.

Notes to Editors

levonorgestrel

ECP is necessary for women who may be concerned about the possibility of an unwanted pregnancy following unprotected intercourse. Two large multinational studies, aiming to test a 12-24h regimen (Lancet, 1999) and a single administration (Lancet, 2002), both performed by the World Health Organisation (WHO) demonstrated that levonorgestrel mono therapy, such as NorLevo(R), was safe and more effective than the Yuzpe method (ethinyl estradiol and levonorgestrel), a traditional emergency contraception method used since 1977. Levonorgestrel mono therapy for emergency contraception is listed as an essential drug by the WHO.

About Sosei

Sosei Group is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit http://www.sosei.com


'/>"/>
SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sosei Announces Outcome of Strategy Review
2. Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
3. Deloitte Agrees to Acquire Recombinant Capital, A Leading Life Sciences Subscription Database and Advisory Services Firm
4. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
5. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
6. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
7. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
8. 2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer
9. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ROCKLAND, Massachusetts and NEW YORK ... Second Biologics License Application accepted by the FDA for avelumab  ... when the disease has metastasized   ... Darmstadt, Germany , in the US and ... that the US Food and Drug Administration (FDA) has accepted ...
(Date:2/27/2017)... , Feb. 27, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ... their expiry on Friday, February 24, 2017 a total of ... price of $0.13 per common share. Proceeds from the exercise ... issued from InMed,s Treasury.   ... "We are grateful for this expression of ...
(Date:2/27/2017)... Feb. 27, 2017 Fluxion Biosciences announced today ... has been appointed as a Certified Service Provider ... system will be used in Genetracer Biotech,s novel liquid ... and colon cancer, with plans to move to other ... utilizing Fluxion,s IsoFlux System to isolate, recover, and analyze ...
(Date:2/25/2017)... Garden City, New York (PRWEB) , ... February ... ... announced their partnership with Verified Clinical Trials in an ongoing effort ... the areas of treatment, advocacy, and pharmaceutical research with emphasis on consumers and ...
Breaking Biology Technology:
(Date:2/2/2017)...  Central to its deep commitment to honor ... Japan Prize Foundation today announced the laureates of ... envelope in their respective fields of Life Sciences ... being recognized with the 2017 Japan Prize for ... to the advancement of science and technology, but ...
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... growing genetic information companies, today announced that it will ... and provide 2017 guidance on Monday, February 13, 2017, ... that day at 4:45 p.m. Eastern / 1:45 p.m. ... team will briefly review financial results, guidance, and recent ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements ... Management (IAM) lifecycle is comprised of a comprehensive ... the purpose of maintaining digital identities and providing ... and applications. There are significant number of programs ... time to time by optimizing processes and changing ...
Breaking Biology News(10 mins):